Other researchers have reported a co-regulation between RANKL and DKK-1 expression in different diseases, such as prostate cancer [30], osteosarcoma [31], and in children with 21-hydroxylase deficiency on chronic glucocorticoid treatment [32]. Here, DKK1 is linked to prostate carcinoma.